Optomed - Health technology company

The Nokia comparison isn’t one-to-one, of course, but it’s an appealingly fitting image to form. However, in the case itself, this is precisely where one must be ready to change their stance if evidence emerges, and I’d gladly have a reasonably sized stake in play to see whether the solution has a chance of disrupting this model.

Yeah, with company-funded ones, there’s obviously always an interest in getting a good result. Over there, for instance, it says that the 317 subjects in the aeye-2 study were taken from among the subjects of the aeye-1 study (531 people). It doesn’t explain how. A skeptic immediately notes that the sample was selected at this point, perhaps by choosing subjects who are easy to image.

Aeye-3 was conducted across five centers over 7 months; 365 were screened and 362 were enrolled. I assume there was some pre-screen selection here too, because A) 3/365 is an extremely low number of ineligible subjects considering the exclusion criteria, and B) between 1,750 and 21,000 clients visited the five centers over 7 months. (This estimate is from an AI)

P.S. In Optomed’s interim report, the net profit and cash flow were naturally positive. You could say a turnaround occurred, but is it permanent? My own analysis focuses on more fundamental factors, and I’m not a numbers guy. So, no reason to change my bearish view based on just one quarter.

4 Likes

It’s kind of amusing reading these forums sometimes. Before earnings, the bears go:
“earnings will be just as bad as always”
“Q3 earnings will set the direction”
“the market is pricing in a bad Q3”

earnings are out and looking juicy, then after that:

“no point celebrating based on just one earnings report”
“the next earnings will set the direction”
“this earnings report didn’t even matter”

Buying more here, the turnaround has happened and there’s no stopping it now. Next stop €2.2

22 Likes

A continuation regarding Signify Health’s fundus imaging.

The results are sent to the patient by mail: Link showing the form.

The result sent by mail MIGHT indicate that the fundus image is interpreted by a physician.

AI thoughts on the matter:

From an investor’s perspective, the key question is: does Signify’s clinician receive an immediate AI result from the fundus imaging during the home visit, or are the images sent later for human interpretation?

Based on the research, the answer at the moment is: there is evidence of traditional remote image interpretation in Signify’s home visit fundus imaging, but I cannot confirm that all or current examinations are interpreted by humans. Nor did I find evidence that Signify has implemented AEYE-DS autonomous AI screening across its entire home visit network.

However, I found two particularly relevant sources to evaluate the matter.

1. Signify’s current patient instructions do not promise an immediate AI result

Signify’s own patient page states that during a home visit, a clinician can examine the eyes with a special camera without pupil dilation. After the visit, Signify can provide the patient with a care plan and share the information with their primary care physician. The page does not mention AI or an immediate screening result.

Signify Health

Signify Health – Annual In-Home Health Evaluation

This alone does not prove human image interpretation. Patient instructions may be intentionally general in nature.

2. In Signify’s insurance partner guide, results are sent by mail

I found a Blue Cross Blue Shield provider guide naming Signify Health as an in-home service provider. The guide mentions diabetic retinal exams and states that a letter and results will be sent by mail.

content.bcbst.com

Blue Cross Blue Shield – In-Home Screening Partners

This aligns with the Signify checklist form you found. However, it does not specify who interprets the images. Mailing could also simply be an administrative delivery method for results generated by an autonomous AI.

3. Is there evidence of human interpretation?

Yes, there is evidence of this in the service model associated with Signify’s operations.

An article published in 2023 covering the collaboration between IRIS and AEYE Health describes two different operating models:

  • In IRIS’s traditional teleretinal service, images are sent to the IRIS Reading Center, where ophthalmologists and retina specialists interpret them.
  • AEYE-DS’s autonomous AI, on the other hand, analyzes the images without actual human diagnostic interpretation.

In the article, the CEO of AEYE Health stated that he hoped IRIS’s clients could in the future also utilize AEYE technology in the approximately 150,000 annual in-home retinal screenings.

Eyes On Eyecare

This is an interesting historical clue: in 2023, AEYE described in-home deployment as a future possibility, not as an already widely implemented reality.

However, it does not prove that the in-home network in question was Signify, or that the situation remains the same in 2026.

1 Like

Oulu has woken up, just as was hoped for :blush:

9 Likes

According to AI, quality measurement documents from US insurance companies show that the following companies use code CPT 92229, i.e., AI-based retinal imaging.

Important note: 11 states have an identified state-specific document. The other 39 are still unconfirmed, not negative results. Guidelines from national insurance companies are also included.

  1. UnitedHealthcare
  2. Fidelis Care
  3. Ohana Health Plan / Wellcare
  4. Arizona Complete Health
  5. Blue Shield of California Promise Health Plan
  6. Iowa Total Care
  7. Ambetter from Sunflower Health Plan
  8. Superior HealthPlan
  9. Coordinated Care
  10. Meridian Health Plan / MeridianComplete
  11. Commonwealth Care Alliance
  12. WellSense Health Plan
  13. Alliance Health Plan
  14. Molina Healthcare
  15. Johns Hopkins Health Plans
  16. Aetna(signity health)
  17. MVP Health Care
  18. Health Plan (healthplan.org)
  19. CMS (federal quality measure, not an insurance company)
6 Likes

Looks like posts have been cleaned up; I’ll still bring these up:

@Jummijammi2 “Opto can choose to be smarter and produce (and secure) the best AI for its Lumoo and Auroora.” – Competition among AI developers will undoubtedly continue for quite some time; they choose partners on whose hardware their products run, etc. Assuming that other high-quality, FDA-cleared hardware will hit the market later on, are there any other solid theses for preventing an AI partner from defecting besides a potential “established position”?

@apjm “Nokia also didn’t grasp the rise of the app ecosystem to the same extent as Apple.” – Yes, i.e., Apple’s focus can be seen as having been more on what people want to do with the device → that is, why someone came up with the idea to start developing screening AI in the first place, for instance. Paranoid Optimist is a good book. In Opto’s story, where AI is the application, I’m pondering the hardware provider’s opportunities if that turns into a highly contested field.

2 Likes

According to Signify Health’s own text, physicians interpret the camera images. One would imagine that AI would be cheaper.

1 Like

Good points and reflection. It really is worth considering Optomed’s moat. At the moment, the situation looks good in DR screening, being the only FDA-cleared handheld device. Aeye Health has also cemented its position quite well through integrations, etc. Aeye Health is unlikely to start using another camera, as that would require an FDA clearance application—which is very laborious to get—and I see no point in applying for a new clearance with another camera. Now the time for oculomics is approaching, and hopefully Optomed knows how to pick the right partners and there’s demand for collaboration with Optomed. The most natural route, of course, would be to enter oculomics together with Aeye Health, which is already on the way in the form of Aeye X. If I recall correctly, isn’t there also an FDA application underway with Toku for cardiovascular diseases? Hopefully, Aeye Health will soon release more information about that X platform. Then there’s also the BP partnership, which we haven’t heard anything about for a while now.

1 Like

I’d like to return to this holy grail of FDA approval. It’s great that we have one. I’m wondering what significance it actually holds for the future (given that there are plenty of unapproved solutions on the market). Taking into account, for example, global optician chains, home care & elder care services, etc., etc. As I understand it, taking the image doesn’t require any specialized skills. If the AI detects a diagnosis, the natural next step is certified professional help (doctors). I wonder whether the market outside FDA approval (e.g., APAC, Aus, Eur & Afr) might actually be larger than just this US regulatory approval in the US. How much does China, for instance, even require anything from the FDA? If so, attention should also be paid to volume growth in new market segments (instead of conservative and slow healthcare care pathways). This, in turn, should definitely translate into massive growth figures in upcoming quarters… Time will tell..

Well, Optomed’s view is that the rest of the world will follow suit, and we do have good algorithms for many applications.

The US is just the clearest business case because it is backed by big money

1 Like

FDA clearance/approval is very significant and, as far as I understand, mandatory if one wants to get their device covered by healthcare in the US. So, Optomed is the only one with FDA clearance for AI-assisted DR (diabetic retinopathy) screening. Others do have FDA clearances, of course, but not for AI-assisted screening. If AI-assisted screening doesn’t become widespread in the future, Optomed’s position isn’t anything special. The rest of the world follows FDA clearances quite closely, so it’s a major advantage in other market areas as well. Optician chains and the like are another matter, but FDA clearance is likely pretty essential on that side too.

To put it simply, which are there more of in the world: opticians/optometrists or ophthalmologists? FDA & Optometry and AI is already yesterday’s news and the present reality. Where is the biggest and most massive future potential: that’s where the gaze, direction & focus should be…

The meat of the business case is avoiding the cost of an ophthalmologist – do optometrists perhaps have a good reason, motive, and use case for AI-assisted retinal screening? Do they require FDA clearance?

Let’s remember once again how this world works.

It’s not that a customer wants the FDA stamp just because it looks nice. The stamp is wanted for legal protection, credibility, and liability reasons. There isn’t a single operator that would adopt a good, well-functioning device + service (which lacks the stamp), because when some unlucky customer goes blind, you’d need water cannons to clear the drooling lawyers off the lawn.

edit. I understood that you were questioning @Jummijammi2 the need for the FDA stamp?

What’s the problem? Opto has already had an FDA-approved solution for these for some time now..

Each country has its own regulatory approvals, and in itself, FDA clearance probably serves mostly as a stamp of quality elsewhere. In China, through the Wiser joint venture, Optomed uses some Chinese AI, and in Europe, Aireen’s AI, which has received CE marking in Europe. Personally, I can’t really comment on whether optical retail chains would have demand for fundus cameras that lack any official clearance, but I’d assume they, too, would prefer an FDA-cleared camera. So in that sense, Optomed is in a good position. Perhaps it’s not worth discussing these clearances and such much further, and it’s better to move on to more interesting and relevant topics surrounding Optomed. I’d imagine the largest and most reliable demand for Optomed’s cameras currently lies within healthcare, but optical retail stores also hold good potential. In China, too, an optical chain had already piloted Optomed’s cameras.

4 Likes

As an aside, Aireen seems to have reasonably good ground to stand on in Europe, as it is involved in the EU-funded multi-country DIGI4Care screening pilot. The pilot was likely agreed upon before the collaboration with Optomed was announced, given that tabletop cameras are still being used in the pictures.

18 Likes

Probably the biggest healthcare event in the US, HLTH Las Vegas, is happening this weekend. Conveniently, AEYE Health is around the corner with the 2026 Prix Galien trophy under their arm. Might be quite a buzz at their booth + wonder if there’s any other recognition regarding this…?

17 Likes

AI-based fundus screening is being expanded to optical stores in Slovakia, and the illustration photo in STVR’s news article features Optomed’s Lumo.

According to the original press release on the website of the Slovak Blind and Partially Sighted Union, the optical chain Alensa is launching AI-based fundus screening in Košice and plans to expand the service to its other locations across the country.

Alensa is a European optical retail chain with Czech roots. The chain has 13 stores in Slovakia. Alensa has announced plans to increase its number of brick-and-mortar stores, particularly in Central Europe. In 2026, it has expanded its store network in countries such as the Czech Republic, Hungary, and Poland.

The potential spread of Alensa’s screening concept to other European countries would open up an interesting growth opportunity for Optomed. A new distribution channel could emerge for Lumo cameras through optical chains, alongside traditional hospitals and health centers.

If you dig a bit, more information starts trickling in. Based on this next link, operations are also underway in Bratislava.

The comment from Alensa’s head of retail network sounds quite promising:

“We are intentionally introducing AI-based eye examinations in Slovakia, specifically in Košice and Bratislava. We have long been aware of the issues surrounding waiting times and the strong interest in this service. We expect this technology to be deployed across our other operations throughout Slovakia in the coming months.”

46 Likes

And in Vietnam, they are presenting…. There would also be room for cameras there, and plenty of them;

25 Likes